Can a Doctor Prescribe BPC-157 in 2026? What the PCAC Vote Changed, and What It Didn't
Last updated: November 18, 2026 · 11 min read · By the Grey Peptides Editorial Board
- A doctor can write a prescription for BPC-157. None of the law's three routes for a compounding pharmacy covers it: BPC-157 has no USP monograph, is in no approved drug, is not on the 503A bulks list, and is not in Category 1 1 2 5. Since October 30, 2026, HHS says it will not take enforcement action against a licensed 503A pharmacy that compounds it under the conditions of its interim policy 6; our legal-access page sets out that route.
- In July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend BPC-157 for the bulks list 3. FDA calls its advisory committees' recommendations non-binding, so the vote changes nothing until FDA acts 8.
- As of October 27, 2026, FDA has not acted: the nominated-substances list still reads 'Updated May 14, 2026', and no rule has appeared in the Federal Register 5 10.
- BPC-157 is graded Low on our evidence scale. FDA found five clinical studies of it; the only randomised, placebo-controlled one, in ulcerative colitis, was presented as a meeting abstract, and FDA judged its data inadequate to support efficacy or safety 2.
The short answer
A licensed prescriber can write a prescription for anything, including BPC-157. Whether a pharmacy can fill it is a different question. as of October 27, 2026 the statute gave no route for a compounded US product; since October 30, 2026 HHS's interim policy says it will not enforce that against a licensed 503A pharmacy meeting its conditions (the legal route, step by step).
The committee recommended BPC-157, but a recommendation is not a rule. Until FDA either places BPC-157 in Category 1 of its nominated substances or adds it to the 503A bulks list through regulation, a compounding pharmacy has no lawful way to make it 1.
BPC-157 is also not an approved drug: FDA's briefing for the meeting says there is no approved product containing it in any country, so there is no manufactured product to prescribe instead 2.
How a compounding pharmacy is allowed to use a substance
A 503A pharmacy, the kind that compounds a drug for an individual patient on a prescription, may use a bulk drug substance in only three situations. FDA's interim policy quotes them from the statute: the substance has an applicable USP or National Formulary monograph; or, if no monograph exists, it is a component of a drug FDA has approved; or, failing both, it appears on a list the Secretary develops through regulations under section 503A 1.
BPC-157 meets none of the three. FDA's briefing states that it has no applicable USP or National Formulary monograph and is not a component of an FDA-approved drug 2. The third route, the 503A bulks list, is the one the July vote was about.
The bulks list is built through notice-and-comment rulemaking 3. To bridge that, FDA uses an interim policy: it does not intend to take regulatory action against a 503A pharmacy compounding with a substance that has no monograph and is not in an approved drug, if, among other conditions, the substance appears in Category 1 of FDA's nominated-substances list 1. Category 1 is therefore the practical door. BPC-157 is not in it.
How BPC-157 got here
The July vote did not come out of nowhere. FDA's page on bulk drug substances that may present significant safety risks lists BPC-157 among substances nominated but withdrawn (content current as of April 22, 2026). Its summary of the risks says compounded BPC-157 may pose a risk of immunogenicity for certain routes of administration, may have complexities with peptide-related impurities and characterising the active ingredient, and that the agency has identified no, or only limited, safety-related information for the proposed routes 4. FDA's briefing for the July meeting records that the nominations for BPC-157 were withdrawn by the nominators and that FDA elected to present it to the committee anyway 2.
BPC-157 appears in none of the three categories of the nominated-substances list today 5. The committee's recommendation is a step in a process FDA has not finished, and the substance's regulatory position is unresolved rather than favourable.
On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 under the forms, routes and conditions in its Appendix B 6. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).
FDA's own briefing documents for the July meeting set out the agency staff's reasoning compound by compound, and they are worth reading alongside the vote: FDA proposed that none of the seven peptides be included on the bulks list, in either form, and the committee recommended six of them anyway 7 3. Those documents are linked from the meeting page and from each compound's page on our PCAC hub 8.
What the committee actually voted
The Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to consider seven peptides for the 503A bulks list 8. It recommended six and rejected one 3 9.
| Compound | Committee vote | Outcome | Our evidence grade |
|---|---|---|---|
| BPC-157 | 8–6, 1 abstention | Recommended | Low |
| KPV | 8–6, 1 abstention | Recommended | Low |
| TB-500 | 8–6, 1 abstention | Recommended | Low |
| MOTS-c | 7–5, 2 abstentions | Recommended | Low |
| Semax | 8–5, 1 abstention | Recommended | Medium |
| Epitalon | 7–4 or 7–5, 1 abstention | Recommended | Low |
| Emideltide (DSIP) | 6–7, 1 abstention | Not recommended | Medium |
The margins were narrow. Four of the recommendations, BPC-157, KPV, TB-500 and MOTS-c, passed by two votes. FDA has not published minutes or tallies, so every tally here is as reported by a law firm and the trade press; the reports we read agree on everything except epitalon's 'no' count, which McDermott gives as 4 and RAPS Regulatory Focus as 5 3 9. The outcome is not in dispute.
Two things are worth noticing in that table. Every recommended compound except semax carries our lowest evidence grade, and a recommendation to allow compounding is not a finding that a substance works. FDA asked the committee to weigh four criteria together: the substance's physical and chemical characterisation, safety issues in compounded products, the available evidence of effectiveness or its lack, and historical use in compounding 7. That is not the approval standard. The full vote record, with each compound's briefing, is on our PCAC hub.
What FDA has done since
Nothing that changes access, as of October 27, 2026. We checked each of the places an action would appear on October 27, 2026.
The nominated-substances list. FDA's list of bulk drug substances nominated for 503A compounding still reads 'Updated May 14, 2026'. None of the seven compounds the committee considered appears in any of its three categories. Category 2, the list of substances raising significant safety risks, now names only cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine for intrauterine use 5.
The Federal Register. Adding a substance to the 503A bulks list requires a rule, and a rule begins with a proposal published in the Federal Register. No FDA document on 503A bulk drug substances has been published there since July 1, 2026 10.
The meeting record. FDA's page for the July meeting was last updated on August 6, 2026, and carries no minutes or transcript 8. The 503A list itself says FDA intends to consult the committee again before the end of February 2027, on a different substance 5.
The absence from Category 2 is easy to misread. FDA lists BPC-157 among nominated-but-withdrawn substances with its safety concerns 4; not being in Category 2 today does not mean FDA has cleared it. It means BPC-157 is in none of the categories, which leaves it outside the interim policy altogether 1.
The access reality, step by step
For a patient asking whether they can get BPC-157 through a doctor, the chain looks like this as of October 27, 2026.
- The prescription. A prescriber can write one. Nothing in the law stops the act of writing it.
- An approved product. There is none. FDA's briefing says no product containing BPC-157 is approved in any country, so no pharmacy can dispense a manufactured product 2.
- A 503A compounding pharmacy. It may use a bulk substance only through a monograph, an approved-drug component, or the bulks list, and in practice Category 1 under the interim policy. BPC-157 has none of these, so a 503A pharmacy has no lawful basis to compound it 1.
- A 503B outsourcing facility. These operate under a separate statutory section, which lets them use a bulk substance without a monograph only if it is on FDA's list of substances with a clinical need or the drug is on the shortage list 11. The July vote concerned the 503A list and does not open this route 8.
- Research chemicals. A product labelled 'for research use only, not for human consumption' is not a prescription drug dispensed by a pharmacy, so buying one is not filling a prescription.
The same chain applies to the other five recommended compounds, with one difference for semax: FDA's briefing calls it a registered drug in Russia, sold there as nasal drops, and says it is not a component of an FDA-approved drug 12. A foreign registration does not open a 503A route.
What to make of clinics that offer it
If a clinic or telehealth service offers BPC-157 as a prescription product, the chain above makes the claim worth a direct question: which pharmacy fills it, and under which of the three statutory routes? BPC-157 is still outside Category 1 and off the bulks list; since October 30, 2026 the only federal cover is HHS's interim non-enforcement policy, which requires a licensed 503A pharmacy, a patient-specific prescription, single-ingredient products in set forms and a 'Not for resale' label. A service supplying it outside those conditions is relying on something else.
The answer may be a research-chemical supplier, an overseas source, or a reading of the rules FDA does not share. None of those is the same as a prescription drug dispensed by a US pharmacy under FDA's framework, and a patient is entitled to know which it is before injecting anything.
None of this is a judgement about the people who want BPC-157. It is a description of where the legal line sits as of October 27, 2026, so that the choice is made with the facts in view.
What would change the answer
Two FDA actions would open the 503A route, and either would be visible on the day it happened. FDA could move BPC-157 into Category 1 of the nominated-substances list, which would bring it under the interim policy while the bulks-list rule proceeds; that is an administrative change to a web document. Or FDA could publish a proposed rule in the Federal Register to add it to the 503A bulks list, which starts notice and comment.
FDA is not bound by the committee: its meeting page says advisory committees make non-binding recommendations 8. And the briefing documents its own staff prepared for July proposed that none of the seven be included 7. A law firm's summary of the meeting expected FDA to begin notice-and-comment rulemaking on the recommended peptides, in a process that could run into 2027 or longer 3.
We re-read the list, the Federal Register and the meeting page at every regulatory watch, and this article is re-dated each time. The regulatory tracker carries the current status of every compound the committee considered.
Why the evidence question has not gone away
Compounding access and evidence of benefit are separate questions, and the July vote settled neither for good. FDA's briefing found five clinical studies of BPC-157 in its literature search: rectal enemas in healthy people, a randomised placebo-controlled ulcerative colitis study known only from a meeting abstract, knee and bladder injections, and an intravenous infusion in two healthy people. It judged the colitis data inadequate to support efficacy or safety 2. Our encyclopedia entry lists what exists in people.
A committee vote to permit compounding sits awkwardly beside the evidence grades in the table above: the committee was asked whether these substances should go on the bulks list, not whether they work. A patient weighing BPC-157 should hold those two answers apart.
For sport, the question is closed regardless of compounding. BPC-157 is prohibited at all times under WADA's S0 section, which names it among its examples 13.
Frequently asked questions
Can a doctor prescribe BPC-157?
A doctor can write the prescription. There is no approved BPC-157 product, and it is not on the 503A bulks list, but since October 30, 2026 HHS says it will not act against a licensed 503A pharmacy that compounds it for a named patient under its interim policy's conditions.
Is BPC-157 legal in the US?
It is not an approved drug and not on the 503A bulks list. Since October 30, 2026, HHS's non-binding interim policy says it will not act against licensed 503A pharmacies compounding it under set conditions. A product labelled for research use only is not a prescription route.
Did FDA approve BPC-157 in 2026?
No. FDA's compounding advisory committee recommended adding it to the 503A bulks list in July 2026, by 8 votes to 6 with 1 abstention. That is advice to FDA, which had not acted as of October 27, 2026.
What would make BPC-157 available from a compounding pharmacy?
FDA moving it into Category 1 of its nominated-substances list, or publishing a rule adding it to the 503A bulks list. Neither had happened as of October 27, 2026.
Is BPC-157 allowed in sport?
No. WADA prohibits it at all times under section S0, which covers any pharmacological substance not addressed elsewhere on the List that has no current approval by a government health authority for human therapeutic use; S0 names BPC-157 among its examples.
Related on Grey Peptides
- BPC-157 encyclopedia entry
- PCAC July 2026 hub
- What research use only means
- BPC-157: the legal prescription route
- Regulatory tracker
Sources
- U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Guidance for industry, January 2025 (revised; replaces the January 2017 guidance). Read October 27, 2026. FDA
- U.S. Food and Drug Administration. BPC-157 briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated May 11, 2026): monograph and approval status, five clinical studies, nomination history. Read October 27, 2026. FDA
- McDermott Will & Schulte (law firm). Bulk list bound? PCAC backs majority of peptides in two-day public meeting, July 27, 2026: votes per peptide (BPC-157, KPV and TB-500 8-6-1; MOTS-c 7-5-2; epitalon 7-4-1; semax 8-5-1; emideltide 6-7-1, not recommended); 'FDA scientists recommended against inclusion of the peptides'; expected notice-and-comment rulemaking. A law-firm summary, not an FDA record. Read October 27, 2026. Cited without a link.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: BPC-157 (nominated but withdrawn). Content current as of April 22, 2026; read October 27, 2026. FDA
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Categories 1, 2 and 3). Updated May 14, 2026; read October 27, 2026. FDA
- US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
- U.S. Food and Drug Administration. Briefing document introduction, Pharmacy Compounding Advisory Committee, July 23-24, 2026: the four evaluation criteria and FDA's proposal that each of the seven substances not be included on the 503A bulks list. Read October 27, 2026. FDA
- U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: agenda, roster and briefing documents. Content current as of August 6, 2026; read October 27, 2026. No minutes, transcript or tallies posted; tallies on this page are from the McDermott and RAPS reports. FDA
- Eglovitch, J. S. FDA advisory committee backs two more peptides, rejects one for compounding list. RAPS Regulatory Focus (trade press), July 24, 2026: epitalon 7-5 with one abstention; semax 8-5; emideltide 6-7 with one abstention. Read October 27, 2026. Cited without a link.
- Federal Register. Search of FDA documents on 503A bulk drug substances published since July 1, 2026: no proposed or final rule on the 503A bulks list and no new Pharmacy Compounding Advisory Committee meeting notice. Searched October 27, 2026. Federal Register
- 21 U.S.C. 353b(a)(2)(A), outsourcing facilities: a bulk drug substance must appear on the list of substances 'for which there is a clinical need' or the drug must be on the drug shortage list. Text read October 27, 2026 (Legal Information Institute). Cited without a link.
- U.S. Food and Drug Administration. Semax briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: 'Semax is a registered drug in Russia and is available as 0.1% and 1% nasal drops.' Read October 27, 2026. FDA
- World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0, non-approved substances (names BPC-157). Read October 27, 2026. WADA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. This article describes regulatory status and is not legal or medical advice; a prescriber and a licensed pharmacist are the people to ask about a specific case.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead